Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women

[1]  J. Long,et al.  Discovery of rare coding variants in OGDHL and BRCA2 in relation to breast cancer risk in Chinese women , 2019, International journal of cancer.

[2]  Xiaohui Xie,et al.  Identifying novel constrained elements by exploiting biased substitution patterns , 2009, Bioinform..

[3]  J. Long,et al.  Discovery of a Pathogenic Variant rs139379666 (p. P2974L) in ATM for Breast Cancer Risk in Chinese Populations , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[4]  Gord Glendon,et al.  10-year performance of four models of breast cancer risk: a validation study. , 2019, The Lancet. Oncology.

[5]  R. Ling,et al.  Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer , 2018, International journal of cancer.

[6]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[7]  S. Manley,et al.  Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.

[8]  A. Gunjur.  Talazoparib for BRCA-mutated advanced breast cancer. , 2018, The Lancet. Oncology.

[9]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[10]  Peter Kraft,et al.  Use of deep whole-genome sequencing data to identify structure risk variants in breast cancer susceptibility genes , 2018, Human molecular genetics.

[11]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[12]  Yuntao Xie,et al.  Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients , 2017, Clinical Cancer Research.

[13]  Keith Nykamp,et al.  Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria , 2017, Genetics in Medicine.

[14]  John Kidd,et al.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Ng,et al.  SIFT missense predictions for genomes , 2015, Nature Protocols.

[16]  Hui Yang,et al.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.

[17]  Y. Qiao,et al.  Breast Cancer Disparities: A Multicenter Comparison of Tumor Diagnosis, Characteristics, and Surgical Treatment in China and the U.S. , 2015, The oncologist.

[18]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[19]  E. Winer,et al.  TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[21]  Xiaohui Xie,et al.  DANN: a deep learning approach for annotating the pathogenicity of genetic variants , 2015, Bioinform..

[22]  Colin Campbell,et al.  An integrative approach to predicting the functional effects of non-coding and coding sequence variation , 2015, Bioinform..

[23]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[24]  Chun Li,et al.  Improved Variant Calling Accuracy by Merging Replicates in Whole-Exome Sequencing Studies , 2014, BioMed research international.

[25]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[26]  Menachem Fromer,et al.  Using XHMM Software to Detect Copy Number Variation in Whole‐Exome Sequencing Data , 2014, Current protocols in human genetics.

[27]  P. Mehdipour,et al.  A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer , 2013, BioMed research international.

[28]  S. Cross,et al.  CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  X. Ye,et al.  Increased risk of breast cancer in women with NF1 , 2012, American journal of medical genetics. Part A.

[30]  Bradley P. Coe,et al.  Copy number variation detection and genotyping from exome sequence data , 2012, Genome research.

[31]  X. Shu,et al.  Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study , 2011, BMC Cancer.

[32]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[33]  Serafim Batzoglou,et al.  Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..

[34]  Jana Marie Schwarz,et al.  MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.

[35]  Wei Lu,et al.  Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. , 2010, Journal of the National Cancer Institute.

[36]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[37]  S. Gruber,et al.  Genetic/familial high-risk assessment: breast and ovarian. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[38]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[39]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[40]  N. Rothman,et al.  Family history of malignancies and risk of breast cancer: prospective data from the Shanghai women’s health study , 2008, Cancer Causes & Control.

[41]  C. Sander,et al.  Determinants of protein function revealed by combinatorial entropy optimization , 2007, Genome Biology.

[42]  D. Reich,et al.  Population Structure and Eigenanalysis , 2006, PLoS genetics.

[43]  D. Easton,et al.  BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families , 2005, Breast Cancer Research.

[44]  N. Rothman,et al.  The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. , 2005, American journal of epidemiology.

[45]  B. Haffty,et al.  Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  B. Ward,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[49]  Sitao Wu,et al.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA Oncology.

[50]  Chad A. LaGrange,et al.  NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[51]  S. Friedman,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[52]  K. Pollard,et al.  Detection of nonneutral substitution rates on mammalian phylogenies. , 2010, Genome research.